

**SESSION 3. INTERACTIVE WORKSHOPS****Workshop session 1**

(Delegates choose one of the following parallel workshops)

14:00 The right drug for the right patient:  
Understanding patient selection in SPAF  
*Kálmán Tóth, András Komócsi; Hungary*

Adherence and non-adherence in SPAF:  
Understanding the issues and solutions  
*Dénes Páll, Gábor Kerecsen; Hungary*

The single drug approach for VTE treatment:  
Understanding and applying the evidence  
*Zsolt Pécsváradý, Katalin Farkas; Hungary*

Practical recommendations for use of the novel oral anticoagulants  
*Róbert Gábor Kiss, Dániel Aradi; Hungary*

**Workshop session 2**

15:00 Repeat of the above workshops

16:00 *Coffee break*

**Workshop session 3**

16:20 Repeat of the above workshops

17:20 Summary and closing remarks  
*Róbert Gábor Kiss, Hungary*

**Programme Chairs:**

**Fausto Pinto**, Portugal

**Sylvia Haas**, Germany

**National Chair:**

**Róbert Gábor Kiss**, Hungary

The **PRO-ACTION Roadshow** is an educational programme intended to provide practical instruction on responsible use of the novel oral anticoagulants. The programme comprises two distinct parts. The first part, made up of Sessions 1 and 2 and taking place in the morning, is an independent, **CME-accredited** expert meeting, with international faculty. This part is delivered in English with translation provision as required, and is supported by an educational grant from Bayer HealthCare.

The second part of the programme, comprising 3 workshop sessions and taking place in the afternoon, is directly organised by Bayer with national faculty and delivered in the local language.

**OPTIMISING PATIENT OUTCOMES WITH THE NOVEL ORAL ANTICOAGULANTS**

# PRO-ACTION

## ROADSHOW 2014

**BUDAPEST, HUNGARY, 29 OCTOBER**

BOSCOLO BUDAPEST

1073 BUDAPEST, ERZSÉBET KÖRÚT 9.

## AGENDA

Dear colleague,

It gives us great pleasure to invite you to join us for the **PRO-ACTION Roadshow 2014** meeting meeting on **29 October 2014** at the **Hotel Boscolo** in **Budapest, Hungary**.

The recently introduced novel oral anticoagulants are increasingly impacting on clinical practice, and their place in therapy is highlighted in recent guidelines. This programme is intended to support appropriate use of these agents in clinical practice, with a particular focus on stroke prevention in atrial fibrillation and the treatment of venous thromboembolism.

This 1-day meeting is divided into two parts. In the morning sessions, which will be conducted in English and submitted for **CME accreditation** through **EBAC** and **EACCME**, an invited international faculty will, through plenary presentations, case studies and panel discussions, provide important new information on appropriate use of the new agents and the challenges of implementing change in clinical practice. In the afternoon session, which will be conducted in Hungarian, national experts will lead a series of small-group interactive workshops exploring some of the themes touched on in the morning sessions in much greater detail. You will have the opportunity to attend three out of the four workshops over the course of the afternoon session.

We very much hope that participation in this meeting will leave us all better prepared to provide optimal care for our patients with or at risk for arterial and venous thromboembolic disease.

We look forward to meeting you in Budapest in October.



Professor Fausto Pinto  
Co-chair, PRO-ACTION Roadshow 2014



Professor Sylvia Haas  
Co-chair, PRO-ACTION Roadshow 2014

INDEPENDENT, CME-ACCREDITED EXPERT MEETING

08:45 Welcome and introduction  
*Róbert Gábor Kiss, Hungary*

### SESSION 1. THE NEW STANDARD OF CARE IN NON-VALVULAR ATRIAL FIBRILLATION

09:00 Real-world experience with the novel oral anticoagulants in atrial fibrillation  
*Fausto Pinto, Portugal*

09:15 Which patients benefit most from the novel oral anticoagulants?  
*Christoph Bode, Germany*

09:45 **Case study 1:** Recommendations for use of the novel oral anticoagulants in patients with compromised renal function  
*Dan Atar, Norway*

10:00 **Case study 2:** Recommendations for use of the novel oral anticoagulants in AF patients experiencing ACS  
*Dan Atar, Norway*

10:15 Audience question and answer session with panel discussion

---

10:45 *Coffee break*

---

### SESSION 2. CHANGING THE STANDARD OF CARE IN THE TREATMENT OF VENOUS THROMBOEMBOLISM

11:05 Real-world experience with the novel oral anticoagulants in venous thromboembolism  
*Sylvia Haas, Germany*

11:20 Simplifying the treatment of venous thromboembolism with a single-drug regimen  
*Ander Cohen, UK*

11:50 **Case study 3:** Controversies in VTE treatment  
*Ander Cohen, UK, moderated by Sylvia Haas, Germany*

12:20 Audience question and answer session with panel discussion

12:50 Closing remarks  
*Fausto Pinto, Portugal*

---

13:00 *Lunch*

---